Lorraine L. Lipscombe, MD
Lipscombe LL. Exenatide did not reduce major cardiovascular outcomes in type 2 diabetes. Ann Intern Med. ;167:JC67. doi: 10.7326/ACPJC-2017-167-12-067
Download citation file:
Published: Ann Intern Med. 2017;167(12):JC67.
Cardiology, Coronary Risk Factors, Diabetes, Endocrine and Metabolism.
Results provided by:
Copyright © 2018 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use